Severe cardiomyopathy following treatment with the tumour necrosis factor-alpha inhibitor adalimumab for Crohn's disease.
Adalimumab belongs to the group of tumour necrosis factor-alpha inhibitors and has been approved for the treatment Crohn's Disease since 2007. Herein we report a severe adverse reaction to adalimumab in a 25-year-old female patient. One week after the initial-dose of adalimumab (160 mg), which was initiated due to an acute exacerbation of Crohn's disease, the patient developed a fulminant cardiomyopathy. In severe cardiogenic shock, the patient required an extracorporeal membrane-oxygenation system for 8 days until cardiac recovery.
Emmert
Maximilian Y
MY
Department of Cardiovascular Surgery, University Hospital Zurich, 8091 Zurich, Switzerland. maximilian_emmert@web.de
Salzberg
Sacha P
SP
Emmert
Lorenz S
LS
Behjati
Sohil
S
Plass
Andre
A
Felix
Christian
C
Falk
Volkmar
V
Gruenenfelder
Juerg
J
D000068879:Adalimumab; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000628:therapy; D003424:Crohn Disease / Q000188:drug therapy*; D015199:Extracorporeal Membrane Oxygenation; D005260:Female; D006801:Humans; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*
D000893:Anti-Inflammatory Agents; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D014409:Tumor Necrosis Factor-alpha; D000068879:Adalimumab